We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AlloCSC
Previous Study | Return to List | Next Study

Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI (CAREMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02439398
Recruitment Status : Completed
First Posted : May 8, 2015
Last Update Posted : November 14, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:

Development of myocardial reparative therapy for the treatment of acute ischemic cardiac disease, based on the intracoronary administration of allogeneic Cardiac Stem Cells (CSCs) to ameliorate myocardial cell death and promote cardio-regeneration.

The study comprises two phases:

  1. Initial dose-escalation open-label safety phase comprising 6 patients. Escalation will start with the Maximum Recommended Safe Dose (MRSD) calculated from Non-Observed Adverse Events Level (NOAEL) and it is expected to finish with the target dose (TD). There will be no placebo group for this initial phase.
  2. Randomized double-blind placebo-controlled safety and efficacy phase in which the TD will be injected if the dose-escalation phase is completed successfully.

Condition or disease Intervention/treatment Phase
Acute Myocardial Infarction Biological: Allogeneic human cardiac stem cells (CSCs) Other: Human Serum Albumin-HSA 5% Phase 1 Phase 2

Detailed Description:

This is a "First in Patient" Clinical Trial to obtain safety and efficacy results about the intracoronary administration of a suspension of allogeneic cardiac stem cells (CSCs) for the treatment of ST elevation Myocardial Infarction (STEMI). This clinical trial will have a first dose-escalation phase in which the safety of 10, 20 and 35 million CSCs administration will be evaluated in 6 patients. A second double-blind randomized and placebo controlled phase will be initiated, if no major safety effects are observed during the first week after cell administration. The 35 million cells dose is the one expected to be used during the randomized phase.

Patients with EF<45% and with infarct sizes > 25% will be selected by magnetic resonance image (MRI). 49 patients will be included in the randomized phase with the aim of having 38 patients for efficacy analysis at the end of the follow up period (12 months). In this phase, patients will be randomly allocated for receiving CSCs or placebo in a 2:1 scheme. Three bioequivalent cellular batches obtained from different donors will be indistinctly used during the assay.

CSCs or placebo treatment will be infused into the coronary artery responsible for the ischemic event. Placebo will be a commercial preparation of human serum albumin 5% in saline solution that will also be used for cell product reconstitution.

After treatment, patients will be monitored overnight in a coronary care unit for any toxicity and discharged from hospital 24h after treatment if no adverse events are observed.

Subsequent safety follow-up will be done first at day 7 after treatment and then monthly or quarterly thereafter for 12 months. In addition, efficacy evaluations will be performed by MRI and clinical parameters at 1, 6 and 12 months after treatment.

Finally, cellular and humoral immunological response (screening for anti-HLA (Human Leukocyte Antigen) class I and class II antibodies, HLA typing, cross-matching between cells and treated patient and cytokine profiling in blood samples) will be analysed during the clinical trial.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: First-in-human, Double Blind, Randomized With Placebo, Open for the 6 First Patients (Dose Ranging) to Evaluate the Safety and Efficacy of Intracoronary Infusion of Allogeneic Human CSCs in Patients With AMI and Left Ventricular Dysfunction
Actual Study Start Date : June 2014
Primary Completion Date : December 2015
Study Completion Date : November 14, 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Allogeneic human cardiac stem cells
After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
Biological: Allogeneic human cardiac stem cells (CSCs)
Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
Other Name: AlloCSC-01
Placebo Comparator: Placebo: Human Serum Albumin-HSA 5%
After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
Other: Human Serum Albumin-HSA 5%
Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.

Outcome Measures

Primary Outcome Measures :
  1. Safety measured as the number of deaths and number of Major Adverse Cardiac Events (MACE) [ Time Frame: 12 months ]
    The primary objective is to demonstrate the safety of the intra-coronary infusion of allogeneic cardiac stem cells in patients with a 7 days evolution first myocardial infarction and left ventricle dysfunction. Safety will be assessed a) evaluating the number of deaths from any cause within 30 days after cell medicine administration; b) evaluating the number of Major Adverse Cardiac Events (MACE) during the first 30 days (composite endpoint), defined as death from any cause, new Acute Myocardial Infarction (AMI), hospitalization due to Heart Failure (HF), sustained Ventricular Tachycardia (VT), Ventricular Fibrillation (VF), and stroke within 12 months after cell medicine administration.

Secondary Outcome Measures :
  1. Efficacy measured by MRI as the infarct size change [ Time Frame: 6 and 12 months ]
    Change of the Infarct Size as percentage (%) of LV mass analysed by MRI at 6 and 12 months after treatment administration versus screening MRI and 1 month MRI.

  2. Efficacy measured by MRI as the evolution of biomechanical parameters [ Time Frame: 6 and 12 months ]
    Percentage of change of the End Systolic Volume (ESV) and End Diastolic Volume (EDV), of the Wall Motion score as segmental contraction score, of the Sphericity Index, of the Systolic thickening by segment and of the Absolute change of Ejection Fraction (EF) analysed by MRI at 6 and 12 months after treatment administration versus screening MRI and 1 month MRI.

  3. Efficacy measured by MRI as the evolution of edema [ Time Frame: 1 month ]
    Percentage of change in the edema volume analysed by MRI at 1 month after treatment administration versus screening MRI.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients ≥ 18 years of age and ≤ 80 years.
  • Patients presenting a ST-segment-elevation myocardial infarction (STEMI) according to the universally accepted definition found in the STEMI management guide of the European Society of Cardiology
  • Killip ≤ 2 on admission
  • Successful primary coronary revascularization by Percutaneous Coronary Intervention- PCI - (Thrombolysis In Myocardial Infarction [TIMI] = 3) within 12h after the onset of infarct symptoms
  • Bare-metal or drug-eluting stents (DES) of second generation (including new second generation stents, e.g. biolimus, novolimus and bioreabsorbable stents) at coronary revascularization by PCI
  • Ejection Fraction (EF) ≤45% by magnetic resonance imaging (MRI). This MRI will be done between day 3 and day 5 after infarction and will be used as inclusion MRI
  • Infarct size in left ventricle (LV) tested in the screening MRI ≥25% The presence of microvascular obstruction at inclusion MRI is permitted
  • The affected coronary artery is adequate for cells infusion at the administration time. The administration procedure is technically feasible on day 4-7 after coronary revascularization by PCI
  • The patient is stable and in adequate clinical condition to undergo the procedure.

Exclusion Criteria:

  • Participation in another clinical trial in the last 30 days
  • Previous allogeneic transplant (blood transfusions are allowed) or treated with cell or gene therapy
  • Previous Q-wave infarction
  • Significant valve disease, relapsing pericarditis, history of cardiac tamponade, cardiomyopathies
  • Severe stenotic lesions (>90%) in a coronary vessel with size >2.75 mm not treated by PCI at least 24 hours before the baseline MRI study
  • Previous EF≤45%, NYHA > 2 (New York Heart Association Functional Classification) or hospital admission for heart failure before STEMI
  • Sustained VT that does not revert with treatment or requires >6 hours to be controlled in the 48 hours prior to the product administration procedure
  • Complete atrioventricular blockade, or acute left bundle branch block in the 48 hours prior to the product administration procedure
  • History of cardioembolic disease
  • Platelets <100,000 and/or Hb<8.5g/dL
  • Acute or chronic renal failure with creatinine ≥2.5 mg/dl or creatinine clearance ≤30 mL/min
  • Infection with systemic involvement
  • Cancer disease, except that eradicated at least 5 years before inclusion, and without receiving radiotherapy on chest. It is permitted coetaneous non-melanoma neoplasms completely eliminated (at any time) and that do not require subsequent chemotherapy or radiotherapy on chest.
  • Child-Pugh's C stage chronic liver disease
  • Baseline respiratory failure requiring oxygen at home
  • Uncontrolled hypertension at screening despite treatment (systolic blood pressure [BP] ≥180 and/or diastolic BP ≥110)
  • Very poorly controlled diabetes (Hb1Ac ≥8.5 g/dL) or with serious target organ lesion (peripheral vascular disease requiring revascularization or non revascularize)
  • History of autoimmune disease
  • Primary or acquired immune deficiency or immunosuppressant treatment (including treatments with immunosuppressants in the previous three months, or foreseeable need for those treatments during the course of the study).
  • Women who are pregnant or breastfeeding or women of childbearing potential who do not agree to use contraceptives during the study period
  • Life expectancy of less than 2 years for any reason.
  • Allergy to aminoglycoside antibiotics or HSA hypersensitivity
  • Contraindications preventing the use of Magnetic Resonance Imaging: Pacemaker, Implantable cardioverter-defibrillator (ICD), known reaction to gadolinium, claustrophobia, cochlear implants
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02439398

Coretherapix (Tigenix Group)
Tres Cantos, Madrid, Spain, 28760
Sponsors and Collaborators
European Commission
Universitaire Ziekenhuizen Leuven
Saint-Louis Hospital, Paris, France
Hospital General Universitario Gregorio Marañon
Complejo Hospitalario de Navarra
Hospital Clínico Universitario de Valladolid
Hospital Donostia
Hospital Clínico Universitario de Valencia
Hospital Universitario de Salamanca
Hospital Universitario Virgen de la Victoria
Study Director: Marie Paule Richard, MD Coretherapix (Tigenix Group)
More Information